PD-L1 expression was reported to be highest within CIS tumors and granulomata of BCG-resistant patients by Inman et al., leading to the hypothesis that the inhibitory effect of PD-L1 on T cells was negatively impacting BCG therapy efficacy [139]. Here, CD274 is linked to in situ carcinoma.